Nearly $200,000 in corporate- and employee-based support for local and international healthcare organizations in 2018
PHILADELPHIA – January 22, 2019 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it reached a new charitable contribution milestone in 2018. As part of the ERT Global Outreach program, nearly $200,000 was donated to international non- profit organizations and local community associations through a combination of ERT corporate sponsorships and employee outreach efforts.
“All of us at ERT have a genuine passion for improving healthcare, and helping those in need; so it is very rewarding to reach a new milestone in the impact we are making through donations, advocacy and volunteerism at the corporate and local levels.” said James Corrigan, President and CEO of ERT. “We are extremely proud of the good that is coming out of our Global Outreach program and the incredible work our employees are doing to make a difference in the health and well-being of the communities in which we are a part.”
The organizations that ERT and its employees support represent a range of healthcare-improving causes, including multiple cancer, diabetes, and heart disease associations as well as local children’s’ hospitals and family support organizations. In addition to corporate sponsorships and employee-led fund-raising efforts, ERT employees regularly give back to their communities by using designated annual paid time off to volunteer at these organizations.
One of the many organizations that benefit from ERT’s Global Outreach program is Simon’s Heart, a non-profit organization dedicated to raising awareness about the warning signs and conditions that lead to sudden cardiac arrest and death in children and adolescents. Since 2014, every heart screening that Simon’s Heart provides is equipped with ECG machines donated by ERT. Additionally, ERT scientists and expert over-read analysts donate countless time every year analyzing ECG readings and uploading the vast data collected for the advancement of life-saving research across the United States.
“Without ERT’s support we simply could not achieve our mission of keeping children alive and healthy,” said Darren Sudman, CEO and Co-founder, Simon’s Heart. “In 2018 alone, ERT enabled us to screen for heart abnormalities in nearly 2,000 children and adolescents in the U.S. These screenings, which are typically not conducted in standard pediatric practice, are critical in identifying the risks of sudden cardiac arrest. We are extremely grateful to ERT and look forward to continuing our relationship into 2019 and beyond.”
About ERT ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials. ERT’s solutions measure treatment efficacy, ensure patient safety, enable effective data integration and analytics, and deliver real-world insights so that its customers can move ahead with confidence.
Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions in 13,000+ studies, spanning more than three million patients to date. By identifying trial risks before they become problems, ERT enables its customers to bring clinical treatments to patients quickly ─ and with confidence.